VYGR
Voyager Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.82
−0.55%Oct 27, 2026, 12:01 UTC
Voyager Therapeutics, Inc. announced that two posters on its investigational tau-targeted therapies VY1706 and VY7523 are planned for presentation at the CTAD conference in Boston on November 16–19, 2026.
Source:Aug 13, 2026, 07:33 UTC
Dimensional Fund Advisors LP reduced its stake in Voyager Therapeutics, Inc. by 19.3%, selling 208,931 shares during the quarter, leaving 875,568 shares, as disclosed in a 13F filing.
Source:Aug 6, 2026, 00:00 UTC
Voyager Therapeutics reported Q2 2026 financial results with revenue of $3.2 million, a net loss of $24.5 million, and diluted EPS of -$0.40.
Jun 1, 2026, 12:00 UTC
The U.S. Food and Drug Administration cleared Voyager Therapeutics' Investigational New Drug application for VY1706, a gene therapy for Alzheimer's disease.
Source: